Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.

Kazuki Takasaki Morikazu Miyamoto Masashi Takano Hiroaki Soyama Tadashi Aoyama Hiroko Matuura Kento Kato Takahiro Sakamoto Mika Kuwahara Hideki Iwahashi Hiroki Ishibashi Tomoyuki Yoshikawa Kenichi Furuya

Published in: Cancer chemotherapy and pharmacology (2018)

Bev-Gem regimens improved PFS and OS for PROC. Furthermore, the adverse effects of Bev-Gem were tolerable. Thus, Bev-Gem could be a candidate treatment strategy for PROC.

Keyphrases

emergency department
squamous cell carcinoma
radiation therapy
combination therapy
replacement therapy
electronic health record